XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   220,978      
Beginning balance at Dec. 31, 2021 $ 790,987 $ 221 $ 2,009,945 $ (1,087) $ (1,218,092)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (81,499)       (81,499)
Other comprehensive income (2,998)     (2,998)  
Issuance of common stock in conjunction with equity plans (in shares)   3,351      
Issuance of common stock in conjunction with equity plans 5,592 $ 3 5,589    
Share-based compensation expense 22,496   22,496    
Ending balance (in shares) at Mar. 31, 2022   224,329      
Ending balance at Mar. 31, 2022 $ 734,578 $ 224 2,038,030 (4,085) (1,299,591)
Beginning balance (in shares) at Dec. 31, 2022 226,505 226,505      
Beginning balance at Dec. 31, 2022 $ 562,904 $ 227 2,099,782 (4,765) (1,532,340)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (88,015)       (88,015)
Other comprehensive income 2,841     2,841  
Shares issued (in shares)   20,125      
Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs 189,200 $ 20 189,180    
Issuance of common stock in conjunction with equity plans (in shares)   3,173      
Issuance of common stock in conjunction with equity plans 7,235 $ 3 7,232    
Share-based compensation expense $ 17,952   17,952    
Ending balance (in shares) at Mar. 31, 2023 249,803 249,803      
Ending balance at Mar. 31, 2023 $ 692,117 $ 250 $ 2,314,146 $ (1,924) $ (1,620,355)